Facial Erythema Treatment Market by Product and Geography - Forecast and Analysis 2022-2026
- Published: Feb 2022
- Pages: 120
- SKU: IRTNTR72324
Enjoy complimentary customisation on priority with our Enterprise License!
Single User:
Quick and easy buy and download option
Enterprise:
Flexible option - Complimentary customization included
The facial erythema treatment market share is expected to increase by USD 106.32 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.01%.
This facial erythema treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers facial erythema treatment market segmentation by product (topical and oral) and geography (North America, Europe, Asia, and ROW). The facial erythema treatment market report also offers information on several market vendors, including Bausch Health Companies Inc., Bayer AG, Galderma SA, GlaxoSmithKline Plc, LEO Pharma AS, Merck and Co. Inc., Novartis AG, Pfizer Inc., and Regeneron Pharmaceuticals Inc. among others.
What will the Facial Erythema Treatment Market Size be During the Forecast Period?
Download the Free Report Sample to Unlock the Facial Erythema Treatment Market Size for the Forecast Period and Other Important Statistics
Facial Erythema Treatment Market: Key Drivers, Trends, and Challenges
The strategic initiatives of market players is notably driving the facial erythema treatment market growth, although factors such as side effects associated with facial erythema treatment drugs may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the facial erythema treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Facial Erythema Treatment Market Driver
The strategic initiatives of market players is one of the key drivers supporting the facial erythema treatment market growth. Vendors in the global facial erythema treatment market are increasingly focusing on strategic developments, such as product enhancements and innovations, to extend their product portfolios. For instance, in July 2021, Sol-Gel Technologies Ltd., a dermatology company that develops generic topical drug products for the treatment of skin diseases, announced that the FDA had approved its first proprietary drug product, TWYNEO. The product is a tretinoin/benzoyl peroxide-based cream, which can be used for the treatment of lesions caused due to acne vulgaris in adults and pediatric patients nine years of age and older. Thus, the growing number of product development and collaborations undertaken by vendors in the market is expected to support the growth of the market during the forecast period.
Key Facial Erythema Treatment Market Trend
The increased healthcare spending worldwide is another factor supporting the facial erythema treatment market growth. According to The World Health Organization (WHO), the global spending on healthcare continually increased between 2000 and 2018 and reached $8.3 trillion or 10% of global GDP. In 2020, the US spent 19.7% of its GDP on healthcare expenditure. Other European nations such as Germany, France, Sweden, and Austria spent 11.43%, 11.26%, 10.90%, and 10.33%, respectively, of their GDP on healthcare expenditure. Furthermore, the expenditure on prescription drugs and over-the-counter medicines has increased in recent years. Thus, the increasing expenditure in the global healthcare sector and the increase in government aid to healthcare providers will boost the growth of the global facial erythema treatment market during the forecast period.
Key Facial Erythema Treatment Market Challenge
The side effects associated with facial erythema treatment drugs is one of the factors hindering the facial erythema treatment market growth. The FDA has provided approval for the topical use of oxymetazoline 0.05% solution for the treatment of rosacea. The usage of oxymetazoline has resulted in improvement in facial erythema and erythematous flares as it offers relief in stinging and burning of the skin. However, many side effects of oxymetazoline have been reported. These include application site dermatitis, pain, paresthesia, and pruritus. It can also lead to the worsening of facial inflammatory lesions of rosacea. Thus, the side effects associated with the usage of facial erythema treatment drugs can result in the reduced usage of these drugs. These market challenges can negatively impact the growth of the global facial erythema treatment market during the forecast period.
This facial erythema treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Parent Market Analysis
Technavio categorizes the facial erythema treatment market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the facial erythema treatment market during the forecast period.
Who are the Major Facial Erythema Treatment Market Vendors?
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
- Bausch Health Companies Inc.
- Bayer AG
- Galderma SA
- GlaxoSmithKline Plc
- LEO Pharma AS
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
This statistical study of the facial erythema treatment market encompasses successful business strategies deployed by the key vendors. The facial erythema treatment market is concentrated and the vendors are deploying growth strategies such as the launch of new products, product approvals, joint ventures, acquisitions, partnerships, expansion projects, collaborations, and investments to compete in the market.
Product Insights and News
- Bausch Health Companies Inc. - The company offers facial erythema treatment that provides effective treatment for pulsed dye, pulsed KTP, and pulsed Nd YAG lasers, and IPL sources, using large spot sizes to avoid reticulation.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The facial erythema treatment market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Facial Erythema Treatment Market Value Chain Analysis
Our report provides extensive information on the value chain analysis for the facial erythema treatment market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
- Research and development (R&D) and drug discovery
- Integration and product development
- Manufacturing
- Outbound logistics
- Marketing and sales
- Support activities
- Innovations
The report has further elucidated on other innovative approaches being followed by service providers to ensure a sustainable market presence.
Which are the Key Regions for Facial Erythema Treatment Market?
For more insights on the market share of various regions Request for a FREE sample now!
41% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the facial erythema treatment market in North America. Market growth in this region will be slower than the growth of the market in Asia.
The high prevalence of rosacea will facilitate the facial eryth`ema treatment market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
In 2020, the COVID-19 pandemic had a negative impact on the regional facial erythema treatment market. The governments of various countries such as the US, Canada, and Mexico, imposed nationwide lockdowns to curb the spread of the disease. However, in H2 2020, due to the availability of vaccines and the vaccination drives conducted by governments in the region, there was a reduction in the number of COVID-19 cases. Supply chain disruptions faced by regional vendors were eased, which led to the availability of various medications for the treatment of facial erythema. Thus, the regional market will continue to witness growth during the forecast period.
What are the Revenue-generating Product Segments in the Facial Erythema Treatment Market?
To gain further insights on the market contribution of various segments Request for a FREE sample
The facial erythema treatment market share growth by the tropical segment will be significant during the forecast period. Facial erythema can be caused by common inflammatory skin diseases such as perioral dermatitis, rosacea, and systemic illness. Various factors leading to facial erythema include sun exposure, extreme temperatures, alcohol consumption, hot drinks, and spicy food, among others. There are several types of facial erythema, with different patterns and color variations like red, purple, or brown. They can be treated with various drugs, which can be administered topically. Thus, the market segment will continue to witness growth due to the increased preference for using topical drugs for the treatment of facial erythema.
This report provides an accurate prediction of the contribution of all the segments to the growth of the facial erythema treatment market size and actionable market insights on post COVID-19 impact on each segment.
|
Facial Erythema Treatment Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.01% |
|
Market growth 2022-2026 |
$ 106.32 million |
|
Market structure |
Concentrated |
|
YoY growth (%) |
4.50 |
|
Regional analysis |
North America, Europe, Asia, and ROW |
|
Performing market contribution |
North America at 41% |
|
Key consumer countries |
US, Germany, UK, China, and Canada |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
Bausch Health Companies Inc., Bayer AG, Galderma SA, GlaxoSmithKline Plc, LEO Pharma AS, Merck and Co. Inc., Novartis AG, Pfizer Inc., and Regeneron Pharmaceuticals Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
What are the Key Data Covered in this Facial Erythema Treatment Market Report?
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will drive facial erythema treatment market growth during the next five years
- Precise estimation of the facial erythema treatment market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the facial erythema treatment industry across North America, Europe, Asia, and ROW
- A thorough analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of facial erythema treatment market vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1. Executive Summary
2. Market Landscape
2.1 Market ecosystem
Exhibit 01: Parent market
Exhibit 02: Market characteristics
2.2 Value chain analysis
Exhibit 03: Value chain analysis: Pharmaceuticals
2.2.1 Research and development (R&D) and drug discovery
2.2.2 Integration and product development
2.2.3 Manufacturing:
2.2.4 Outbound logistics
2.2.5 Marketing and sales
2.2.6 Support activities
2.2.7 Innovations
3. Market Sizing
3.1 Market definition
Exhibit 04: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 05: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021 - 2026
3.4.1 Estimating growth rates for emerging and high-growth markets
3.4.2 Estimating growth rates for mature markets
Exhibit 06: Global - Market size and forecast 2021 - 2026 ($ million)
Exhibit 07: Global market: Year-over-year growth 2021 - 2026 (%)
4. Five Forces Analysis
4.1 Five Forces Summary
Exhibit 08: Five forces analysis 2021 & 2026
4.2 Bargaining power of buyers
Exhibit 09: Bargaining power of buyers
4.3 Bargaining power of suppliers
Exhibit 10: Bargaining power of suppliers
4.4 Threat of new entrants
Exhibit 11: Threat of new entrants
4.5 Threat of substitutes
Exhibit 12: Threat of substitutes
4.6 Threat of rivalry
Exhibit 13: Threat of rivalry
4.7 Market condition
Exhibit 14: Market condition - Five forces 2021
5. Market Segmentation by Product
5.1 Market segments
The segments covered in this chapter are:
- Topical
- Oral
Exhibit 15: Product- Market share 2021-2026 (%)
5.2 Comparison by Product
Exhibit 16: Comparison by Product
5.3 Topical - Market size and forecast 2021-2026
Exhibit 17: Topical - Market size and forecast 2021-2026 ($ million)
Exhibit 18: Topical - Year-over-year growth 2021-2026 (%)
5.4 Oral - Market size and forecast 2021-2026
Exhibit 19: Oral - Market size and forecast 2021-2026 ($ million)
Exhibit 20: Oral - Year-over-year growth 2021-2026 (%)
5.5 Market opportunity by Product
Exhibit 21: Market opportunity by Product
6. Customer landscape
Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
Exhibit 22: Customer landscape
7. Geographic Landscape
7.1 Geographic segmentation
The regions covered in the report are:
- North America
- Europe
- Asia
- ROW
Exhibit 23: Market share by geography 2021-2026 (%)
7.2 Geographic comparison
Exhibit 24: Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 25: North America - Market size and forecast 2021-2026 ($ million)
Exhibit 26: North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 27: Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 28: Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 29: Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Asia - Year-over-year growth 2021-2026 (%)
7.6 ROW - Market size and forecast 2021-2026
Exhibit 31: ROW - Market size and forecast 2021-2026 ($ million)
Exhibit 32: ROW - Year-over-year growth 2021-2026 (%)
7.7 Key leading countries
Exhibit 33: Key leading countries
7.8 Market opportunity by geography
Exhibit 34: Market opportunity by geography ($ million)
8. Drivers, Challenges, and Trends
8.1 Market drivers
8.1.1 Strategic initiatives of market players
8.1.2 Changing climatic conditions
8.1.3 High demand for antibiotics for the treatment of rosacea
8.2 Market challenges
8.2.1 Side effects associated with facial erythema treatment drugs
8.2.2 Stringent government regulations
8.2.3 Increased use of generic drugs
Exhibit 35: Impact of drivers and challenges
8.3 Market trends
8.3.1 Increased healthcare spending worldwide
8.3.2 Growth in R&D related to dermatological diseases
8.3.3 Increased rate of patient population
9. Vendor Landscape
9.1 Overview
Exhibit 36: Vendor landscape
9.2 Landscape disruption
Exhibit 37: Landscape disruption
Exhibit 38: Industry risks
10. Vendor Analysis
10.1 Vendors covered
Exhibit 39: Vendors covered
10.2 Market positioning of vendors
Exhibit 40: Market positioning of vendors
10.3 Bausch Health Companies Inc.
Exhibit 41: Bausch Health Companies Inc. - Overview
Exhibit 42: Bausch Health Companies Inc. - Business segments
Exhibit 43: Bausch Health Companies Inc. - Key offerings
Exhibit 44: Bausch Health Companies Inc. - Segment focus
10.4 Bayer AG
Exhibit 45: Bayer AG - Overview
Exhibit 46: Bayer AG - Business segments
Exhibit 47: Bayer AG-Key news
Exhibit 49: Bayer AG - Segment focus
10.5 Galderma SA
Exhibit 50: Galderma SA - Overview
Exhibit 51: Galderma SA - Product and service
Exhibit 52: Galderma SA - Key offerings
10.6 GlaxoSmithKline Plc
Exhibit 53: GlaxoSmithKline Plc - Overview
Exhibit 54: GlaxoSmithKline Plc - Business segments
Exhibit 55: GlaxoSmithKline Plc - Key offerings
Exhibit 56: GlaxoSmithKline Plc - Segment focus
10.7 LEO Pharma AS
Exhibit 57: LEO Pharma AS - Overview
Exhibit 58: LEO Pharma AS - Business segments
Exhibit 59: LEO Pharma AS - Key offerings
Exhibit 60: LEO Pharma AS - Segment focus
10.8 Merck and Co. Inc.
Exhibit 61: Merck and Co. Inc. - Overview
Exhibit 62: Merck and Co. Inc. - Business segments
Exhibit 63: Merck and Co. Inc. - Key offerings
Exhibit 64: Merck and Co. Inc. - Segment focus
10.9 Novartis AG
Exhibit 65: Novartis AG - Overview
Exhibit 66: Novartis AG - Business segments
Exhibit 67: Novartis AG - Key offerings
Exhibit 68: Novartis AG - Segment focus
10.10 Pfizer Inc.
Exhibit 69: Pfizer Inc. - Overview
Exhibit 70: Pfizer Inc. - Business segments
Exhibit 71: Pfizer Inc. - Key offerings
Exhibit 72: Pfizer Inc. - Segment focus
10.11 Regeneron Pharmaceuticals Inc.
Exhibit 73: Regeneron Pharmaceuticals Inc. - Overview
Exhibit 74: Regeneron Pharmaceuticals Inc. - Product and service
Exhibit 75: Regeneron Pharmaceuticals Inc. - Key offerings
11. Appendix
11.1 Scope of the report
11.1.1 Market definition
11.1.2 Objectives
11.1.3 Notes and caveats
11.2 Currency conversion rates for US$
Exhibit 76: Currency conversion rates for US$
11.3 Research Methodology
Exhibit 77: Research Methodology
Exhibit 78: Validation techniques employed for market sizing
Exhibit 79: Information sources
11.4 List of abbreviations
Exhibit 80: List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Frequently Asked Questions?
- US
- Germany
- UK
- China
- Canada
- Strategic initiatives of market players
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Single User:
Quick and easy buy and download option
Enterprise:
Flexible option - Complimentary customization included
2500 USD
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Technavio Insights
Did you know?
Did you know?
Did you know?
Customized Report as per your Business Needs
- Our analysts will work directly with you and understand your needs
- Get data on specified regions or segments, competitor and Vendors
- Data will be formatted and presented as per your requirements
- We offer $1000 worth of FREE customization at the time of purchase
Let us help you make report more suited to your requirements.
- Get a competitive breakdown as per your niche industry
- Customize the data with various metrics that meet your business prerequisite
- Understand Revenue Sources, Customers and many more
- Details on Market Share
- These customizations are done in a short amount of time by our analysts and industry experts
